SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Friday reported a loss of $178.9 million in its fourth quarter.
On a per-share basis, the Salt Lake City-based company said it had a loss of 53 cents.
The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 36 cents per share.
The biotechnology company posted revenue of $4.5 million in the period, also missing Street forecasts. Three analysts surveyed by Zacks expected $28.7 million.
For the year, the company reported a loss of $463.7 million, or $1.69 per share. Revenue was reported as $58.8 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RXRX at https://www.zacks.com/ap/RXRX
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。